PYC Therapeutics Limited Price Chart
PYC Therapeutics Limited PH7.SG Financial and Trading Overview
| PYC Therapeutics Limited stock price | 0.08 EUR |
| Previous Close | 0.08 EUR |
| Open | 0.08 EUR |
| Bid | 0.08 EUR x 25000000 |
| Ask | 0.1 EUR x 25000000 |
| Day's Range | 0.08 - 0.08 EUR |
| 52 Week Range | 0.08 - 0.12 EUR |
| Volume | 0 EUR |
| Avg. Volume | 25 EUR |
| Market Cap | 275.51M EUR |
| Beta (5Y Monthly) | 0.218007 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.004 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PH7.SG Valuation Measures
| Enterprise Value | 246.57M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 20.377518 |
| Price/Book (mrq) | 11.785714 |
| Enterprise Value/Revenue | 18.237 |
| Enterprise Value/EBITDA | -10.235 |
Trading Information
PYC Therapeutics Limited Stock Price History
| Beta (5Y Monthly) | 0.218007 |
| 52-Week Change | -27.95% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.12 EUR |
| 52 Week Low | 0.08 EUR |
| 50-Day Moving Average | 0.09 EUR |
| 200-Day Moving Average | 0.09 EUR |
PH7.SG Share Statistics
| Avg. Volume (3 month) | 25 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 3.18B |
| Float | 1.23B |
| Short Ratio | N/A |
| % Held by Insiders | 61.41% |
| % Held by Institutions | 0.014% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | -175.16% |
| Operating Margin (ttm) | -182.87% |
| Gross Margin | 100.00% |
| EBITDA Margin | -178.18% |
Management Effectiveness
| Return on Assets (ttm) | -37.023% |
| Return on Equity (ttm) | -70.024% |
Income Statement
| Revenue (ttm) | 13.52M EUR |
| Revenue Per Share (ttm) | 0.004 EUR |
| Quarterly Revenue Growth (yoy) | -42.10% |
| Gross Profit (ttm) | 16.04M EUR |
| EBITDA | -24091852 EUR |
| Net Income Avi to Common (ttm) | -23683510 EUR |
| Diluted EPS (ttm) | -0.004 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 17.08M EUR |
| Total Cash Per Share (mrq) | 0.005 EUR |
| Total Debt (mrq) | 669.09K EUR |
| Total Debt/Equity (mrq) | 2.9 EUR |
| Current Ratio (mrq) | 3.225 |
| Book Value Per Share (mrq) | 0.007 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -26040496 EUR |
| Levered Free Cash Flow (ttm) | -17079228 EUR |
Profile of PYC Therapeutics Limited
| Country | Germany |
| State | WA |
| City | Nedlands |
| Address | Harry Perkins Institute of Med Research |
| ZIP | 6009 |
| Phone | 61 8 6151 0992 |
| Website | https://pyctx.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Q&A For PYC Therapeutics Limited Stock
What is a current PH7.SG stock price?
PYC Therapeutics Limited PH7.SG stock price today per share is 0.08 EUR.
How to purchase PYC Therapeutics Limited stock?
You can buy PH7.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PYC Therapeutics Limited?
The stock symbol or ticker of PYC Therapeutics Limited is PH7.SG.
How many shares does PYC Therapeutics Limited have in circulation?
The max supply of PYC Therapeutics Limited shares is 3.34B.
What is PYC Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
PYC Therapeutics Limited PE Ratio is now.
What was PYC Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
PYC Therapeutics Limited EPS is -0.004 EUR over the trailing 12 months.